{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:26:00Z","timestamp":1794245160307,"version":"4.9.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41591-025-03532-x","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:11:59Z","timestamp":1743495119000},"page":"1183-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-0528","authenticated-orcid":false,"given":"Sandeep S.","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-1715","authenticated-orcid":false,"given":"Teng","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-222X","authenticated-orcid":false,"given":"Shalev","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":false,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1516","authenticated-orcid":false,"given":"Joshua A.","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-1061","authenticated-orcid":false,"given":"Ana","family":"Alarcon Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-7625","authenticated-orcid":false,"given":"Jonathan U.","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivetta","family":"Danylesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Epstein-Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-5644","authenticated-orcid":false,"given":"Tyler","family":"Funnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-8942","authenticated-orcid":false,"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirav","family":"Kedmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Landego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Parascondola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8878-0563","authenticated-orcid":false,"given":"Amethyst","family":"Saldia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8624-7489","authenticated-orcid":false,"given":"Inbal","family":"Sdayoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Shem-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-8793","authenticated-orcid":false,"given":"Benjamin D.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6503","authenticated-orcid":false,"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6912-4157","authenticated-orcid":false,"given":"Hyung C.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0696-4401","authenticated-orcid":false,"given":"Marcel R. M.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"3532_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3532_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3532_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"3532_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"3532_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3532_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"3532_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3532_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"3532_CR9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3532_CR10","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3532_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","volume":"37","author":"A Alarcon Tomas","year":"2023","unstructured":"Alarcon Tomas, A. et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia 37, 154\u2013163 (2023).","journal-title":"Leukemia"},{"key":"3532_CR12","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137, 1832\u20131835 (2021).","journal-title":"Blood"},{"key":"3532_CR13","doi-asserted-by":"crossref","unstructured":"Pennisi, M. et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 4, 676\u2013686 (2020).","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"3532_CR14","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K. et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 4, 3024\u20133033 (2020).","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"3532_CR15","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K. et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 10, 79 (2020).","DOI":"10.1038\/s41408-020-00346-7"},{"key":"3532_CR16","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain, T. et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 4, 3776\u20133787 (2020).","journal-title":"Blood Adv."},{"key":"3532_CR17","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"3532_CR18","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 5607\u20135615 (2020).","journal-title":"Blood Adv."},{"key":"3532_CR19","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi, M. et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 5, 3397\u20133406 (2021).","journal-title":"Blood Adv."},{"key":"3532_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 40, 369\u2013381 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3532_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.1986.4.6.859","volume":"4","author":"S Jagannath","year":"1986","unstructured":"Jagannath, S. et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J. Clin. Oncol. 4, 859\u2013865 (1986).","journal-title":"J. Clin. Oncol."},{"key":"3532_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","volume":"54","author":"AM Ferraris","year":"1979","unstructured":"Ferraris, A. M., Giuntini, P. & Gaetani, G. F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54, 928\u2013932 (1979).","journal-title":"Blood"},{"key":"3532_CR23","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","DOI":"10.1056\/NEJM199309303291402"},{"key":"3532_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","volume":"29","author":"KF Kernan","year":"2017","unstructured":"Kernan, K. F. & Carcillo, J. A. Hyperferritinemia and inflammation. Int. Immunol. 29, 401\u2013409 (2017).","journal-title":"Int. Immunol"},{"key":"3532_CR25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","volume":"5","author":"AR Gholiha","year":"2021","unstructured":"Gholiha, A. R. et al. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. Blood Adv. 5, 1671\u20131681 (2021).","journal-title":"Blood Adv."},{"key":"3532_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"3532_CR27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138, 2499\u20132513 (2021).","journal-title":"Blood"},{"key":"3532_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"3532_CR29","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/315826","volume":"182","author":"M Nagaki","year":"2000","unstructured":"Nagaki, M. et al. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J. Infect. Dis. 182, 1103\u20131108 (2000).","journal-title":"J. Infect. Dis."},{"key":"3532_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.32614\/RJ-2016-021","volume":"8","author":"L Scrucca","year":"2016","unstructured":"Scrucca, L., Fop, M., Murphy, T. B. & Raftery, A. E. mclust 5: clustering, classification and density estimation using Gaussian finite mixture models. R J. 8, 289\u2013317 (2016).","journal-title":"R J."},{"key":"3532_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10543400701376498","volume":"17","author":"L Lin","year":"2007","unstructured":"Lin, L., Hedayat, A. S. & Wu, W. A unified approach for assessing agreement for continuous and categorical data. J. Biopharm. Stat. 17, 629\u2013652 (2007).","journal-title":"J. Biopharm. Stat."},{"key":"3532_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255\u2013268 (1989).","journal-title":"Biometrics"},{"key":"3532_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1477-7525-8-135","volume":"8","author":"JW Kocks","year":"2010","unstructured":"Kocks, J. W. et al. Health status in routine clinical practice: validity of the clinical COPD questionnaire at the individual patient level. Health Qual. Life Outcomes 8, 135 (2010).","journal-title":"Health Qual. Life Outcomes"},{"key":"3532_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.amepre.2020.07.027","volume":"60","author":"L Tuzzio","year":"2021","unstructured":"Tuzzio, L. et al. Barriers to implementing cardiovascular risk calculation in primary care: alignment with the consolidated framework for implementation research. Am. J. Prev. Med. 60, 250\u2013257 (2021).","journal-title":"Am. J. Prev. Med."},{"key":"3532_CR35","doi-asserted-by":"crossref","unstructured":"Harrell, F. E. Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. JAMA 247, 2543\u20132546 (1982).","DOI":"10.1001\/jama.1982.03320430047030"},{"key":"3532_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers, A. J., Cronin, A. M., Elkin, E. B. & Gonen, M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform. Decis. Mak. 8, 53 (2008).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"3532_CR37","doi-asserted-by":"crossref","unstructured":"Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 26, 565\u2013574 (2006).","DOI":"10.1177\/0272989X06295361"},{"key":"3532_CR38","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood-2021-152819","volume":"138","author":"JL Crombie","year":"2021","unstructured":"Crombie, J. L. et al. Prognostic value of early PET in patients with aggressive non-Hodgkin lymphoma treated with anti-CD19 CAR T-cell therapy. Blood 138, 886 (2021).","journal-title":"Blood"},{"key":"3532_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl, A. et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 6, 321\u2013326 (2022).","journal-title":"Blood Adv"},{"key":"3532_CR40","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690\u2013700 (2021).","journal-title":"Br. J. Haematol."},{"key":"3532_CR41","unstructured":"Itacitinib pre-modulation in DLBCL receiving CAR T cell therapy. ClinicalTrials.gov identifier: NCT05757219. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05757219 (2024)."},{"key":"3532_CR42","doi-asserted-by":"publisher","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J. Immunother. Cancer 10, e004475 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3532_CR43","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"3532_CR44","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati, P. et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137, 3272\u20133276 (2021).","journal-title":"Blood"},{"key":"3532_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain, M. D. et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood 140, 491\u2013503 (2022).","journal-title":"Blood"},{"key":"3532_CR46","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"3532_CR47","doi-asserted-by":"crossref","unstructured":"Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances circular visualization in R. Bioinformatics 30, 2811\u20132812 (2014).","DOI":"10.1093\/bioinformatics\/btu393"},{"key":"3532_CR48","doi-asserted-by":"crossref","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"3532_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","volume":"28","author":"M Kedmi","year":"2022","unstructured":"Kedmi, M. et al. Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplant. Cell Ther. 28, 251\u2013257 (2022).","journal-title":"Transplant. Cell Ther."},{"key":"3532_CR50","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3532_CR51","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W. & Tubiana, M. Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res. 31, 1860\u20131861 (1971).","journal-title":"Cancer Res."},{"key":"3532_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3532_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/009286150303700112","volume":"37","author":"J Karvanen","year":"2003","unstructured":"Karvanen, J. The statistical basis of laboratory data normalization. Drug Inf. J. 37, 101\u2013107 (2003).","journal-title":"Drug Inf. J"},{"key":"3532_CR54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/009286150103500117","volume":"35","author":"C Chuang-Stein","year":"2001","unstructured":"Chuang-Stein, C. Some issues concerning the normalization of laboratory data based on reference ranges. Drug Inf. J. 35, 153\u2013156 (2001).","journal-title":"Drug Inf. J."},{"key":"3532_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01908075","volume":"2","author":"L Hubert","year":"1985","unstructured":"Hubert, L. & Arabie, P. Comparing partitions. J. Classif. 2, 193\u2013218 (1985).","journal-title":"J. Classif."},{"key":"3532_CR56","doi-asserted-by":"crossref","unstructured":"Kanoun, S. et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline (18F)FDG PET to predict survival in Hodgkin lymphoma. PLoS ONE 10, e0140830 (2015).","DOI":"10.1371\/journal.pone.0140830"},{"key":"3532_CR57","doi-asserted-by":"crossref","unstructured":"Zwanenburg, A. et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295, 328\u2013338 (2020).","DOI":"10.1148\/radiol.2020191145"},{"key":"3532_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","volume":"17","author":"D Leithner","year":"2024","unstructured":"Leithner, D. et al. Conventional and novel ((18)F)FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. J. Hematol. Oncol. 17, 21 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"3532_CR59","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","volume":"101","author":"A Kumar","year":"2016","unstructured":"Kumar, A. et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica 101, 1237\u20131243 (2016).","journal-title":"Haematologica"},{"key":"3532_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. 34, 187\u2013202 (1972).","journal-title":"J. R. Stat. Soc."},{"key":"3532_CR61","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 9, 811\u2013818 (1990).","journal-title":"Stat. Med."},{"key":"3532_CR62","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/sim.1844","volume":"23","author":"EW Steyerberg","year":"2004","unstructured":"Steyerberg, E. W., Borsboom, G. J., van Houwelingen, H. C., Eijkemans, M. J. & Habbema, J. D. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat. Med. 23, 2567\u20132586 (2004).","journal-title":"Stat. Med"},{"key":"3532_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers, A. J., van Calster, B. & Steyerberg, E. W. A simple, step-by-step guide to interpreting decision curve analysis. Diagn. Progn. Res. 3, 18 (2019).","journal-title":"Diagn. Progn. Res."},{"key":"3532_CR64","unstructured":"Epcoritamab compared to observation for treating B-cell lymphoma patients not in complete remission after CD19-directed CAR-T therapy. ClinicalTrials.gov identifier: NCT06238648. https:\/\/clinicaltrials.gov\/study\/NCT06238648 (2024)."},{"key":"3532_CR65","unstructured":"Testing drug treatments after CAR T-cell therapy in Patients with relapsed\/refractory diffuse large B-cell lymphoma. ClinicalTrials.gov identifier: NCT05633615. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05633615 (2024)."},{"key":"3532_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.62","volume":"8","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni, G. et al. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. Hemasphere 8, e62 (2024).","journal-title":"Hemasphere"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03532-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:02:37Z","timestamp":1744812157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03532-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. reports speaker honorarium from Incyte. A.A. reports honoraria from AbbVie and has consulting and advisory roles with Takeda, Gilead, Novartis, Roche and Bristol Myers Squibb. L.A.L. served as a consultant and\/or speaker bureau for Kite\/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lilly, Epizyme, TG Therapeutics, Merck and ADC Therapeutics. A.I. owns stock and has ownership interests in Cota Healthcare. He also reports honoraria from MJH Life Sciences and Pfizer. He served as a consultant and\/or speaker bureau for TG Therapeutics, Secura Bio, AstraZeneca and Seattle Genetics. Z.E.-P. serves on Genmab advisory board. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics and consulting fees from Da Volterra, CSL Behring and MaaT Pharma. He serves on an advisory board of and holds equity in Postbiotics Plus Research. He has filed intellectual property applications related to the microbiome (reference numbers #62\/843,849, #62\/977,908 and #15\/756,845). R.J.L. has served as a consultant for Kite. G.L.S. has received research funding from Janssen, Amgen, BMS, Beyond Spring, GPCR and Recordati and serves on the DSMB for Arcellx. M.S. served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, Amgen Inc., Bristol Myers Squibb, and Sanofi; served on ad hoc advisory boards for Kite \u2013 A Gilead Company, and Miltenyi Biotec; and received honoraria from i3Health, Medscape, CancerNetwork, Intellisphere LLC, Curio Science LLC, and IDEOlogy. S.A.G. receives research funding from Amgen, Johnson & Johnson, Takeda, Celgene, Actinium, Sanofi, Miltenyi, Kite and EUSA. He is on the advisory boards of Amgen, Johnson & Johnson, Takeda, Celgene, Actinium, Sanofi, Miltenyi, Novartis, Kite, Jazz, BMS, Spectrum Pharma and EUSA Omeros. J.H.P. received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Curocel, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi and Takeda; received honoraria from OncLive, Physician Education Resource and MJH Life Sciences; serves on scientific advisory board of Allogene Therapeutics and Artiva Biotherapeutics; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, Incyte, Servier and Takeda. M.L.P. has served as a consultant for Novartis, Cellectar, Synthekine, Kite, Seres, Magenta, WindMIL, Rheos, Nektar, Notch, Priothera, Ceramedix, Lygenesis and Pluto. G.S. has received in the last 12 months financial compensation for participating in advisory boards or consulting from AbbVie, Atbtherapeutics, Beigene, BMS\/Celgene, Debiopharm, Genentech\/Roche, Genmab, Incyte, Ipsen, Janssen, Kite\/Gilead, Loxo\/Lilly, Merck, Molecular Partners, Nordic Nanovector, Novartis, Nurix and Orna. He has also received research support managed by his institution from Genentech, Janssen and Ipsen. He is a shareholder of Owkin. B.D.G. has received honoraria for speaking engagements from Merck, Bristol Myers Squibb and Chugai Pharmaceuticals; has received research funding from Bristol Myers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies and Rome Therapeutics, of which he is a co-founder. He additionally has intellectual property rights with Rome Therapeutics and the Icahn School of Medicine at Mount Sinai. He has served in an advisory role at Merck Sharpe and Dohme and Darwin Health. M.-A.P. reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite\/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene and Sellas Life Sciences and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite\/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. M.R.M.v.d.B. has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, Lygenesis, Pluto Therapeutics, GlaxoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (spouse), Synthekine (spouse), Beigene (spouse) and Kite (spouse); he has IP licensing with Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). Memorial Sloan Kettering Cancer Center has institutional financial interests relative to Seres Therapeutics. The other authors declare no competing interests. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}